118 related articles for article (PubMed ID: 2438715)
1. Concentration of TSH-receptor antibodies (TBII) in the sera of patients with immunogenic hyperthyroidism (Graves' disease) receiving antithyroid medication.
Budihna N; Pavlin K; Porenta M
Radiobiol Radiother (Berl); 1987; 28(1):101-6. PubMed ID: 2438715
[No Abstract] [Full Text] [Related]
2. Thyroid stimulating immunoglobulin in Graves' disease.
Luttrell BM; Hales IB
Aust N Z J Med; 1981 Jun; 11(3):293-8. PubMed ID: 6170289
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of the assay of TSH-binding inhibitor immunoglobulins (TBII) in patients with Graves' disease: Effect of antithyroid drug treatment on TBII and prognosis].
Iida Y; Konishi J; Kousaka T; Misaki T; Nakajima T; Endo K; Torizuka K
Kaku Igaku; 1983 Dec; 20(10):1425-31. PubMed ID: 6202910
[No Abstract] [Full Text] [Related]
4. Detectability of thyroid anti-microsomal antibodies, changes in thyroid-stimulating immunoglobulins (TSI) and thyrotropin-binding-inhibiting immunoglobulins (TBII) during methimazole treatment of Graves' disease patients.
Szabó J; Leövey A; Karányi Z; Várvölgyi C; Fórizs E; Herceg L
Acta Med Hung; 1989; 46(1):23-30. PubMed ID: 2570399
[TBL] [Abstract][Full Text] [Related]
5. Paired determination of thyroid-stimulating and TSH-binding inhibitory activities in patients with Graves' disease during antithyroid drug treatment.
Kasagi K; Iida Y; Konishi J; Misaki T; Arai K; Endo K; Torizuka K; Kuma K
Acta Endocrinol (Copenh); 1986 Apr; 111(4):474-80. PubMed ID: 2422860
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis.
Wägar G; Mäkinen T; Lamberg BA; Gordin A; Apter L; Pekonen F
Ann Clin Res; 1982 Apr; 14(2):83-9. PubMed ID: 6184007
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of the determination of TSH-binding inhibitory immunoglobulins (TBII) by a radioreceptor assay].
Heberling HJ; Bierwolf B; Lohmann D
Dtsch Z Verdau Stoffwechselkr; 1986; 46(5):301-6. PubMed ID: 2879721
[TBL] [Abstract][Full Text] [Related]
8. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. II. Clinical significance of measuring TSAb and TBII in patients with euthyroid Graves' disease and patients with hyperthyroid Graves' disease during antithyroid drug treatment].
Uno C; Nishikawa M
Nihon Naibunpi Gakkai Zasshi; 1988 Mar; 64(3):206-15. PubMed ID: 2456230
[TBL] [Abstract][Full Text] [Related]
9. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
Wallaschofski H; Kuwert T; Lohmann T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
[TBL] [Abstract][Full Text] [Related]
10. Immunological aspects of Graves' disease and importance of thyroid stimulating immunoglobulins.
Bech K
Acta Endocrinol Suppl (Copenh); 1983; 254():3-38. PubMed ID: 6191508
[No Abstract] [Full Text] [Related]
11. Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.
Uchimura H; Akimoto N; Mitsuhashi T; Kubota K; Kuzuya N; Imai Y; Ikeda H; Matsuzaki F; Kumagai LF
J Endocrinol Invest; 1986 Feb; 9(1):37-42. PubMed ID: 2422245
[TBL] [Abstract][Full Text] [Related]
12. [Hyperthyroidism in Graves' disease--antithyroid drug treatment].
Schumm-Draeger PM
Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():41-5. PubMed ID: 10355049
[TBL] [Abstract][Full Text] [Related]
13. [Clinical relevance of the determination of TSH-binding inhibitory immunoglobulins (TBII) in patients with immunogenic hyperthyroidism in methimazole therapy].
Heberling HJ; Bierwolf B; Kuhlmann E; Klugmann T; Dietel P; Fischer S
Dtsch Z Verdau Stoffwechselkr; 1987; 47(6):331-6. PubMed ID: 2896115
[TBL] [Abstract][Full Text] [Related]
14. In vitro suppression of anti-TSH receptor antibody by autologous anti-idiotypic antibody in patients with Graves' disease.
Balázs C; Molnár I
Acta Microbiol Immunol Hung; 1995; 42(2):163-9. PubMed ID: 7551709
[TBL] [Abstract][Full Text] [Related]
15. Prediction of remission after antithyroid drug treatment in Graves' disease.
Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
[TBL] [Abstract][Full Text] [Related]
16. Detection of TSH-binding inhibiting immunoglobulins in patients with Graves' disease and non toxic goiter.
Mossetti G; Salomone Megna A; Lanzano C; Maddaloni D; Leonello D; Gravina E
Boll Ist Sieroter Milan; 1986; 65(4):277-82. PubMed ID: 2878674
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of Graves' disease--antithyroid drug therapy].
Onaya T
Nihon Rinsho; 1999 Aug; 57(8):1846-50. PubMed ID: 10483263
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
Massart C; Gibassier J; d'Herbomez M
Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
[TBL] [Abstract][Full Text] [Related]
19. Detection of tsh binding inhibiting antibodies (TBI-ab) and thyroid adenylate cyclase stimulating antibodies (TS-ab) in sera of patients with Graves' disease.
Lattanzi V; Scardapane R; Ciampolillo A; Vincenti C; Giorgino R
Boll Soc Ital Biol Sper; 1985 Jan; 61(1):55-60. PubMed ID: 3838478
[TBL] [Abstract][Full Text] [Related]
20. [TSH receptor antibody in hyperthyroid patients due to Graves' disease treated with antithyroid drugs].
Yamada T
Nihon Naibunpi Gakkai Zasshi; 1991 Dec; 67(12):1295-308. PubMed ID: 1723696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
